HighTower Advisors’s TherapeuticsMD TXMD Stock Holding History

HighTower Advisors’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-247	Closed	-$16K	–	3393
2021 Q1	$16K	Buy	+247	New	+$19.3K	﹤0.01%	2913
2018 Q4	–	Sell	-210	Closed	-$69K	–	2368
2018 Q3	$69K	Hold	210	–	–	﹤0.01%	2097
2018 Q2	$65K	Buy	+210	New	+$64.2K	﹤0.01%	2044
2017 Q4	–	Sell	-418	Closed	-$111K	–	2383
2017 Q3	$111K	Buy	+418	New	+$121K	﹤0.01%	2008
2016 Q4	–	Sell	-400	Closed	-$136K	–	2042
2016 Q3	$136K	Hold	400	–	–	﹤0.01%	1706
2016 Q2	$171K	Hold	400	–	–	﹤0.01%	1529
2016 Q1	$128K	Hold	400	–	–	﹤0.01%	1884
2015 Q4	$208K	Hold	400	–	–	﹤0.01%	1727
2015 Q3	$117K	Hold	400	–	–	﹤0.01%	1720
2015 Q2	$157K	Buy	+400	New	+$141K	﹤0.01%	1388
2014 Q1	–	Sell	-482	Closed	-$126K	–	1686
2013 Q4	$126K	Buy	+482	New	+$106K	﹤0.01%	1361

Other funds holding TXMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

HighTower Advisors's TXMD Position: Q2 2021 in Review

HighTower Advisors sold out of TherapeuticsMD (TXMD) in Q2 2021, closing a stake of 247 shares — an estimated $16K sold.

HighTower Advisors first reported a position in TXMD in Q4 2013 and held it in 11 quarters. The position peaked at $208K in Q4 2015. 154 funds tracked by Wall St. Rank hold TXMD as of Q2 2021.

HighTower Advisors reported no remaining TherapeuticsMD position as of Q2 2021 after selling out during the quarter.
HighTower Advisors sold 247 TherapeuticsMD shares in Q2 2021, an estimated $16K.
HighTower Advisors first reported a position in TherapeuticsMD in Q4 2013 and held it in 11 quarters.
HighTower Advisors's TherapeuticsMD position peaked at $208K in Q4 2015.
154 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2021.

Based on HighTower Advisors's 13F filing for Q2 2021, filed 6 Aug 2021.